According to Capricor Therapeutics 's latest financial reports the company's current revenue (TTM) is $27.09 M. In 2022 the company made a revenue of $2.55 M an increase over the years 2021 revenue that were of $0.24 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $25.17 M | 886.81% |
2022 | $2.55 M | 941.85% |
2021 | $0.24 M | -21.06% |
2020 | $0.31 M | -69.13% |
2019 | $1 M | -39.87% |
2018 | $1.67 M | -23.7% |
2017 | $2.19 M | -31.33% |
2016 | $3.19 M | -15.52% |
2015 | $3.77 M | -9.38% |
2014 | $4.16 M | |
2013 | N/A | -100% |
2012 | $0.19 M | -85.57% |
2011 | $1.35 M | |
2010 | N/A | |
2009 | N/A |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | $89.65 B | 330,766.42% | ๐บ๐ธ USA |
Neurocrine Biosciences
NBIX | $1.98 B | 7,214.13% | ๐บ๐ธ USA |
Cytokinetics
CYTK | $3.75 M | -86.15% | ๐บ๐ธ USA |
Celldex Therapeutics CLDX | $6.07 M | -77.59% | ๐บ๐ธ USA |
Palatin Technologies PTN | $5.9 M | -78.22% | ๐บ๐ธ USA |
Eterna Therapeutics ERNA | $0.11 M | -99.58% | ๐บ๐ธ USA |